Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, GLP-1RA, Glucose Monitoring, Other Jul 29 | 2022Dexcom G7 Delayed in US; Dexcom, Pfizer, Biocon, Sanofi, and Teladoc Q2 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: SGLT2i Jul 27 | 2022Lexicon’s Sota HF NDA Accepted by FDA in Patients With and Without T2DMPurchase Blast
$599
Posted in: Basal Insulin, Other Jul 27 | 2022vTv Receives $10M Investment from CinPax, LLC; Oramed Reaches 50% Enrollment in Second Ph3 Oral Insulin Trial; Esperion Establishes Scientific Advisory BoardPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery Jul 22 | 2022Tandem Acquires Capillary Biomedical; Lilly’s Mounjaro Receives Positive CHMP OpinionPurchase Blast
$599
Posted in: Basal Insulin, Glucose Monitoring, Insulin Delivery, Other Jul 20 | 2022Abbott Q2 ’22 Earnings Update; Lilly to Initiate Fourth Trial in Ph3 QWINT Program; Ionis’s Ph3 Lp(a) HORIZON CVOT Completes EnrollmentPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist Jul 19 | 2022Tirzepatide up for CHMP Opinion; July 18-21 CHMP Agenda; Lilly Initiates QW Insulin T2DM MDI Trial (QWINT-4); UHC Eliminates Insulin OOP CostsPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Jul 18 | 2022Abbott Progresses Libre 3 US Launch; New Trial Dasiglucagon Trial for Inreda’s Bi-hormonal AID system; NICE Recommends Amarin’s Vazkepa for Reimbursement in England and WalesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Other Jul 12 | 2022Vertex to Acquire ViaCyte; Another Medtronic Pump Recall; Insulet-Roche Settle Patent Lawsuit; Ionis licenses IgAN Asset to Roche; California to Manufacture Its Own Low-cost Insulin?Purchase Blast
$599
Posted in: Basal Insulin, Other Jul 08 | 2022Viatris Recalls Another Batch of Glargine Vials; Intercept’s OCA Meets Primary Endpoint in New Interim Analysis; Dexcom partners with ZillionPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other, SGLT2i Jul 06 | 2022Novo Initiates Ph3 H2H Sema vs. Empa Trial; CeQur Launches its Simplicity Insulin Patch Pump; Vertex T1DM Clinical Hold LiftedPurchase Blast
$599
Posted in: GLP-1RA Jul 01 | 2022New Oral Sema Primary Prevention CVOT (ASCEND PLUS)Purchase Blast
$599
Posted in: Glucose Monitoring, Other, SGLT2i Jul 01 | 2022Teplizumab Delayed Even Further; Lexicon Wins with LX9211; Novartis Buys a PRV; Nemaura FY ’21 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Other Jun 30 | 2022Novo Sues Orbicular Pharmaceuticals Over Generic Saxenda; Sema Ph2 NASH Trial Disappoints; Kerendia Receives New Recommendations from ADA; Sanofi Cuts Insulin Price and Partners with Direct Relief; Novartis to Cut 8,000 Jobs Worldwide; Lifescan Publishes Connected BGM RWEPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other, SGLT2i Jun 27 | 2022Novo to Initiate Ph1 Sema+Dapa FDC Ph1 Trial; ProKidney Publishes Data Supporting MoA of REACT in Patients with Diabetic CKD; Cytokinetics Announces Date for Omecamtiv FDA Adcom; Hygieia licenses d-Nav program in IsraelPurchase Blast
$599
Posted in: Glucose Monitoring, Other Jun 23 | 2022Novo and Echosens Partnership to Increase NASH Awareness; GlucoTrack to Initiate First In-human Clinical Study for GlucoTrack 2.0Purchase Blast
$599
Posted in: Bolus Insulin, Other Jun 22 | 2022Illinois Expands Insurance Coverage to Include CGMs; Adocia Announces Positive Top-line Results from Ph2 M1Pram Trial; June 20-23 CHMP AgendaPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
